← All trials
NCT05817643
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2023
- Primary completion
- Feb 27, 2023
- Completion date
- Jun 15, 2024
- First posted
- Apr 18, 2023
- Last posted
- Oct 19, 2023
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Allyx TherapeuticsLead sponsor
- Michael J. Fox Foundation for Parkinson's ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.